Metsera
Financing Round
- Series A
Round Led by Symbiosis
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.
View Website
Modality
- Biologic
Indication
- Circulatory & Metabolic Disease
Development Status
- Phase 1